An observational case series of the use of anti-Immunoglobulin E antibody for the management of treatment-resistant systemic mastocytosis.
Dr Karl Bleasel
15 participants
Nov 1, 2009
Interventional
Conditions
Summary
The primary purpose of the study is to observe the effect of anti-immunoglobulin E antibody in the treatment of a small number of people with symptomatic mastocytosis.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Anti-immunoglobulin E antibody will be administered to participants as a subcutaneous injection, at a dose of 375mg (which may be altered during the course of treatment, depending on individual patient response), every fortnight, for a total of 24 weeks, equivalent to twelve doses.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000886280